Αρχική World News Adding Palbociclib to Maintenance Anti-HER2 and Endocrine Therapies Improves PFS Over Standard... World News Adding Palbociclib to Maintenance Anti-HER2 and Endocrine Therapies Improves PFS Over Standard Therapy in Patients with HR-positive, HER2-positive MBC Από Ogkologos - 5 Φεβρουαρίου, 2026 556 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PATINA study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR How Becky is helping her children to keep their dad’s memory... 21 Απριλίου, 2023 NHS England Lung Cancer Screening Programme Demonstrates that it is Feasible and Scalable... 3 Απριλίου, 2026 Results of Continuous vs Intermittent Dosing Schedules of BRAF/MEK Inhibitor Combination... 30 Οκτωβρίου, 2020 Combination immunotherapy for advanced bowel cancer approved for NHS in England 16 Ιουνίου, 2021 Φόρτωση περισσοτέρων HOT NEWS Study Suggests a Link between Stress and Cancer Coming Back Sublobar Resection Noninferior to Lobectomy in Terms of DFS Among Patients... Treatment for Children with Leukemia Also Effective for Adolescents, Young Adults Adding Capivasertib to Fulvestrant Results in Longer PFS in Patients with...